Intra-Cellular Therapies (ITI) has completed phase I clinical study demonstrating ITI-007, the company’s lead antipsychotic drug, interacts with important targets in the living human brain. These key targets
Unilife Medical Solutions (Unilife) has commenced final preparations for the commercial release and sale of its Unitract 1ml syringes, following the completion of device ageing studies for product
Biovator and BASF have signed a collaboration agreement for final development of in-vitro test systems, capable of identifying the potential of chemical compounds to induce allergic reaction in
The European Medicines Agency (EMEA) has granted Cell Therapeutics’ (CTI) Pixantrone, orphan drug designation for the treatment of diffuse large b-cell lymphoma (DLBCL). CTI expects to file the
Actelion has said that the first phase III study with Almorexant (Restora 1) has met its primary endpoint – superiority of the dual orexin receptor antagonist Almorexant compared
Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries: Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies will launch the
The Society of Chemical Manufacturers and Affiliates (SOCMA) has reported that Larry Brotherton, CEO and owner of Ortec was elected Board of Governors chairman during SOCMA’s Annual Meeting
Novartis has announced that the World Health Organization (WHO) has granted prequalification for all three of its influenza A(H1N1) 2009 monovalent vaccines for supply to the UN agencies.
Æterna Zentaris has terminated its agreement with Sanofi-aventis US signed on March 5, 2009 for the development, commercialisation and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for
The Procter & Gamble (P&G) has voluntarily recalled its Vicks DayQuil Cold & Flu 24-Count LiquiCaps Bonus Pack in the US. P&G said it is taking this action
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.